Amoy Diagnostics Co., Ltd. (SHE:300685)

China flag China · Delayed Price · Currency is CNY
20.44
-0.10 (-0.49%)
Apr 29, 2026, 12:34 PM CST
-2.15%
Market Cap 8.03B
Revenue (ttm) 1.20B
Net Income (ttm) 361.26M
Shares Out 391.13M
EPS (ttm) 0.90
PE Ratio 22.82
Forward PE 21.40
Dividend 0.45 (2.02%)
Ex-Dividend Date Jun 3, 2025
Volume 5,257,095
Average Volume 11,339,775
Open 22.17
Previous Close 20.54
Day's Range 20.32 - 22.17
52-Week Range 19.40 - 26.15
Beta 0.55
RSI 35.79
Earnings Date Apr 16, 2026

About Amoy Diagnostics

Amoy Diagnostics Co., Ltd. engages in research and development, production, sale, and supporting services of tumor precision medical diagnostic products in China and internationally. The company offers AmoyDx homologous recombination deficiency (HRD) focus panel solutions, evaluates PARP inhibitor-related biomarkers and advances targeted treatment research in ovarian cancer; AmoyDx comprehensive panel, a sequencing-based test capable of detecting a range of alterations; AmoyDx HRD complete panel, detects genetic aberrations across HRR genes and... [Read more]

Sector Healthcare
Founded 2008
Employees 1,144
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300685
Full Company Profile

Financial Performance

In 2025, Amoy Diagnostics's revenue was 1.20 billion, an increase of 8.01% compared to the previous year's 1.11 billion. Earnings were 361.26 million, an increase of 41.74%.

Financial Statements

News

There is no news available yet.